Commentary

ONC-CHAT: Dr. Martine Piccart, 'Absolutely No Advantage' to 2 Years of Trastuzumab


 

Eight-year follow-up data from the HERA trial confirm that one-year of adjuvant trastuzumab (Herceptin) is better than 2 years -- or none in HER2-positive breast cancer. Bruce Jancin of IMNG Medical Media interviews Dr. Martine Piccart at the San Antonio Breast Cancer Symposium, where she presented encouraging results from this large multinational effort.

Next Article: